U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C14H10N4O
Molecular Weight 250.2554
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of OLPRINONE

SMILES

CC1=C(C=C(C#N)C(=O)N1)C2=CN3C=CN=C3C=C2

InChI

InChIKey=JPAWFIIYTJQOKW-UHFFFAOYSA-N
InChI=1S/C14H10N4O/c1-9-12(6-11(7-15)14(19)17-9)10-2-3-13-16-4-5-18(13)8-10/h2-6,8H,1H3,(H,17,19)

HIDE SMILES / InChI

Description
Curator's Comment: description was created based on several sources, including http://www.eisai.jp/medical/products/di/EPI/COR_A_EPI.pdf

Olprinone (INN) is a cardiotonic agent, is used for treatment acute heart failure. It has been marketed in Japan since 1996. The main mechanism of action of olprinone hydrochloride hydrate is selective inhibition of PDE III specific to cAMP. It is considered that this action causes an increase in intracellular cAMP levels and peak Ca2+ levels, thereby increasing myocardial contractility.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Unknown

Approved Use

Unknown
PubMed

PubMed

TitleDatePubMed
Effects of olprinone, a phosphodiesterase 3 inhibitor, on regional cerebral blood flow of cerebral cortex in stroke patients.
2001 Apr
Use of olprinone, a phosphodiesterase III inhibitor, in an asthmatic patient.
2001 Apr
Effects of olprinone, a new phosphodiesterase inhibitor, on gastric intramucosal acidosis and systemic inflammatory responses following hypothermic cardiopulmonary bypass.
2001 Apr
Cardioprotective effect afforded by transient exposure to phosphodiesterase III inhibitors: the role of protein kinase A and p38 mitogen-activated protein kinase.
2001 Aug 7
A comparison of the relaxant effects of olprinone and aminophylline on methacholine-induced bronchoconstriction in dogs.
2001 Jul
The effects of olprinone (a phosphodiesterase III inhibitor) on hepatic vascular bed in a porcine model of endotoxemia.
2001 Mar
Effect of phosphodiesterase III inhibitor on contractility, afterload, and vascular capacitance during right heart bypass preparation.
2001 Oct
Olprinone: a phosphodiesterase III inhibitor with positive inotropic and vasodilator effects.
2002 Fall
Effect of phosphodiesterase III inhibitor on plasma concentrations of endothelin-1 and tumour necrosis factor in patients with acute heart failure.
2002 Feb
Inhaled olprinone improves contractility of fatigued canine diaphragm.
2002 Mar
[Effects of olprinone hydrochloride on intraocular pressure and ocular blood flow in patients after cardiac surgery under cardiopulmonary bypass].
2002 Nov
Possible contribution of acetylamrinone and its enhancing effects on platelet aggregation under shear stress conditions in the onset of thrombocytopenia in patients treated with amrinone.
2003
Olprinone, a phosphodiesterase III inhibitor, does not affect hypoxia-induced pial arteriolar dilatation in rabbits.
2003 Feb
Toborinone and olprinone, phosphodiesterase III inhibitors, inhibit human platelet aggregation due to the inhibition of both calcium release from intracellular stores and calcium entry.
2004
The phosphodiesterase III inhibitor olprinone decreases sensitivity of rat Kupffer cells to endotoxin.
2004 Aug
Olprinone improves diaphragmatic contractility and fatigability during abdominal sepsis in a rat model.
2004 May
Effects of olprinone on hepatosplanchnic circulation and mitochondrial oxidation in a porcine model of endotoxemia.
2005
Phosphodiesterase 3 inhibition and cough in elderly asthmatics.
2005 Nov 24
Vasoactive drugs and the gut: is there anything new?
2006 Apr
Effects of olprinone on myocardial ischemia-reperfusion injury in dogs.
2006 Aug
The enhancement of cellular cAMP with olprinone protects autotransplanted rat kidney against cold ischemia-reperfusion injury.
2006 Jun
Effects of dopamine and olprinone on ventricular energetics in sevoflurane-induced acute left ventricular depression in dogs.
2006 Jun
Metabolic effects of phosphodiesterase III inhibitors: another reason to promote their use?
2007
[Phosphodiesterase III inhibitor--characteristics, mechanisms of action, pharmacokinetics, indications, contraindications, clinical trials, and side effects].
2007 May 28
[Anesthetic management of coronary artery bypass grafting for unstable angina pectoris in a patient undergoing home oxygen therapy].
2008 Apr
Pharmacological preconditioning in type 2 diabetic rat hearts: the roles of mitochondrial ATP-sensitive potassium channels and the phosphatidylinositol 3-kinase-Akt pathway.
2009 Aug
[A case report of anesthesia for a child with Pompe's disease (glycogen storage disease type II)].
2009 Feb
[Use of cardiovascular drugs for cardiac surgery--based on recent studies].
2009 Mar
A phosphodiesterase III inhibitor protects rat liver from sinusoidal obstruction syndrome through heme oxygenase-1 induction.
2009 May
Local application of olprinone for promotion of peripheral nerve regeneration.
2009 Nov
A phosphodiesterase III inhibitor protects rat liver from sinusoidal obstruction syndrome through heme oxygenase-1 induction.
2010 Apr
Anesthetic management of a patient undergoing liver transplantation who had previous coronary artery bypass grafting using an in situ right gastroepiploic artery.
2010 Apr
Effect of olprinone, a phosphodiesterase III inhibitor, on hepatic ischemia-reperfusion injury in rats.
2010 Apr
Differential vasodilation response to olprinone in rabbit renal and common carotid arteries.
2010 Feb
[Right heart failure during modified ultrafiltration in pediatric living donor lobar lung transplantation].
2010 Feb
Olprinone attenuates the development of ischemia/reperfusion injury of the gut.
2010 Jul
The effects of the phosphodiesterase inhibitor olprinone on global cerebral ischemia.
2010 Mar 1
Ethyl 8-(4-nitro-phen-yl)imidazo[1,2-a]pyridine-7-carboxyl-ate.
2010 Nov 24
Olprinone attenuates the acute inflammatory response and apoptosis after spinal cord trauma in mice.
2010 Sep 7
Patents

Patents

Sample Use Guides

intravenously at a dose of 10 µg/kg of olprinone hydrochloride hydrate, gradually over 5 min, and then drip-infused intravenously at a rate of 0.1 - 0.3 µg/kg/min
Route of Administration: Intravenous
In Vitro Use Guide
E-1020 (Olprinone) may improve diastolic function as well as systolic function in failing hearts. Effects of E-1020, on intracellular calcium transients were compared with those of isoproterenol (ISO) in isolated single myocytes from failing hearts secondary to pulmonary hypertension induced by monocrotaline injection. Myocytes were isolated by enzyme digestion using a Langendorff apparatus. Changes in intracellular calcium concentrations ([Ca2+]i) were recorded using a fura-2 fluorescence microscopic technique.
Name Type Language
OLPRINONE
INN   WHO-DD  
INN  
Official Name English
Olprinone [WHO-DD]
Common Name English
1,2-DIHYDRO-5-IMIDAZO(1,2-.ALPHA.)PYRIDIN-6-YL-6-METHYL-2-OXONICOTINONITRILE
Common Name English
LOPRINONE [MI]
Common Name English
olprinone [INN]
Common Name English
Classification Tree Code System Code
NCI_THESAURUS C744
Created by admin on Sat Dec 16 17:50:04 UTC 2023 , Edited by admin on Sat Dec 16 17:50:04 UTC 2023
Code System Code Type Description
DRUG CENTRAL
1987
Created by admin on Sat Dec 16 17:50:04 UTC 2023 , Edited by admin on Sat Dec 16 17:50:04 UTC 2023
PRIMARY
MESH
C059498
Created by admin on Sat Dec 16 17:50:04 UTC 2023 , Edited by admin on Sat Dec 16 17:50:04 UTC 2023
PRIMARY
ChEMBL
CHEMBL1474900
Created by admin on Sat Dec 16 17:50:04 UTC 2023 , Edited by admin on Sat Dec 16 17:50:04 UTC 2023
PRIMARY
EVMPD
SUB09434MIG
Created by admin on Sat Dec 16 17:50:04 UTC 2023 , Edited by admin on Sat Dec 16 17:50:04 UTC 2023
PRIMARY
EPA CompTox
DTXSID1048461
Created by admin on Sat Dec 16 17:50:04 UTC 2023 , Edited by admin on Sat Dec 16 17:50:04 UTC 2023
PRIMARY
NCI_THESAURUS
C90918
Created by admin on Sat Dec 16 17:50:04 UTC 2023 , Edited by admin on Sat Dec 16 17:50:04 UTC 2023
PRIMARY
PUBCHEM
4593
Created by admin on Sat Dec 16 17:50:04 UTC 2023 , Edited by admin on Sat Dec 16 17:50:04 UTC 2023
PRIMARY
INN
7123
Created by admin on Sat Dec 16 17:50:04 UTC 2023 , Edited by admin on Sat Dec 16 17:50:04 UTC 2023
PRIMARY
WIKIPEDIA
OLPRINONE
Created by admin on Sat Dec 16 17:50:04 UTC 2023 , Edited by admin on Sat Dec 16 17:50:04 UTC 2023
PRIMARY
SMS_ID
100000083335
Created by admin on Sat Dec 16 17:50:04 UTC 2023 , Edited by admin on Sat Dec 16 17:50:04 UTC 2023
PRIMARY
MERCK INDEX
m6902
Created by admin on Sat Dec 16 17:50:04 UTC 2023 , Edited by admin on Sat Dec 16 17:50:04 UTC 2023
PRIMARY Merck Index
CAS
106730-54-5
Created by admin on Sat Dec 16 17:50:04 UTC 2023 , Edited by admin on Sat Dec 16 17:50:04 UTC 2023
PRIMARY
FDA UNII
4Y8BMI9YGC
Created by admin on Sat Dec 16 17:50:04 UTC 2023 , Edited by admin on Sat Dec 16 17:50:04 UTC 2023
PRIMARY